12-Lipoxygenase inhibition delays onset of autoimmune diabetes in human gene replacement mice

Type 1 diabetes (T1D) is characterized by the autoimmune destruction of insulin-producing β cells and involves an interplay between β cells and cells of the innate and adaptive immune systems. We investigated the therapeutic potential of targeting 12-lipoxygenase (12-LOX), an enzyme implicated in in...

Description complète

Détails bibliographiques

Auteurs principaux:	Titli Nargis, Charanya Muralidharan, Jacob R. Enriquez, Jiayi E. Wang, Kerim B. Kaylan, Advaita Chakraborty, Sarida Pratuangtham, Kayla Figatner, Jennifer B. Nelson, Sarah C. May, Jerry L. Nadler, Matthew B. Boxer, David J. Maloney, Sarah A. Tersey, Raghavendra G. Mirmira
Format:	Artigo
Langue:	Inglês
Publié:	American Society for Clinical investigation 2024-12-01
Collection:	JCI Insight
Sujets:	Endocrinology Therapeutics
Accès en ligne:	https://doi.org/10.1172/jci.insight.185299
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!